1080491-31-1

Basic information

• Product Name: N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartaric acid
• Synonyms: N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartaric acid
• CAS NO: 1080491-31-1
• Molecular Weight: 577.65
• Mol File: 1080491-31-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartaric acid(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartaric acid(1080491-31-1)
• EPA Substance Registry System: N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N’-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartaric acid(1080491-31-1)

Safety Data

• Hazardous Substances Data: 1080491-31-1(Hazardous Substances Data)

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 359878-47-0 N- [(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine 
• 1445-73-4 1-Methyl-4-piperidone 
• 5203-15-6 4-(2-methylpropoxy)benzonitrile 
• 459-57-4 4-fluorobenzaldehyde 
• 1194-02-1 4-fluorobenzonitrile 
• 4734-09-2 1-[4-(2-methylpropyloxy)phenyl]methanamine 
• 882035-15-6 4-isobutyloxybenzaldehyde oxime 
• 18962-07-7 4-isobutoxybenzaldehyde 
• 706779-91-1 N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′-(4-(2-methylpropyloxyl)phenylmethyl)carbamide 

Relevant articles and documents

Preparation method of pimavanserin and intermediate thereof

The invention discloses a preparation method of pimavanserin and an intermediate thereof. The preparation method of the intermediate comprises the following steps: in the presence of an alkali, carrying out a reaction on a compound M, a compound SM and carbon dioxide in an organic solvent to obtain a compound A, wherein R is C1-C4 alkyl, benzyl or substituted benzyl, and X is Cl, Br or I. The preparation method has the advantages of simple operation, mild reaction conditions, high yield, low impurity content, easy purification, substantial reduction of the production cost, and easy industrialproduction.

Pimavanserin monotartrate hemihydrate and preparation method thereof

The invention provides a new pimavanserin crystal form, namely a monotartrate hemihydrate; a powder X-ray diffraction pattern of the polycrystal form has diffraction peaks at about (2[theta]+/-0.2 degrees) 7.1 degrees, 15.6 degrees, 18.6 degrees, 20.6 degrees and 22.9 degrees. The crystal form is easy to prepare, simple to operate, and better suitable for preparation of pharmaceutical preparations and large-scale production, and has broad application prospects.